On September 4, 2026, BioRestorative Therapies, Inc. received a resignation notice from Mr. Silva, its Vice President of Research and Development, effective immediately. Silva claims the departure constitutes a resignation for "Good Reason" due to an alleged Change in Control resulting from Board composition changes linked to a June 10, 2026 Revolving Loan Agreement with Bowery Group LLC. He demands approximately $1.29 million in severance, equity acceleration, and benefits. The Company disputes the validity of the Employment Agreement and the Change in Control assertion, reserving all rights while halting payments pending a special counsel investigation into prior executive agreements. BioRestorative Therapies, Inc. operates in the biotechnology industry, focusing on developing cell-based therapies for degenerative diseases.

BioRestorative Therapies, Inc. dismissed CBIZ CPAs P.C. as its independent registered public accounting firm effective August 28, 2026, and engaged Bush & Associates CPA to audit fiscal years ending December 31, 2024, 2025, and 2026. The Board approved the change on August 26, 2026. CBIZ cited a potential reportable event under Item 304(a)(1)(v) of Regulation S-K due to the company's suspension of biocosmeceutical product lines (ExoCR and BioX), which management states may materially impact financial statement reliability if further investigated, though no specific disagreements occurred. An independent investigation into the suspension is ongoing. The company operates in the biotechnology sector, focusing on regenerative medicine and biocosmeceuticals.

BioRestorative Therapies, Inc. announced a one-for-twenty (1-for-20) reverse stock split of its common stock to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The transaction was approved by the Board on August 27, 2026, and filed with the Nevada Secretary of State on September 2, 2026. The split becomes effective at 4:30 p.m. ET on September 7, 2026, with adjusted trading beginning September 8, 2026. Outstanding shares will decrease from approximately 27.6 million to roughly 1.38 million, and authorized common stock will be reduced proportionally from 1.5 billion to 75 million shares. Fractional shares are rounded up to the nearest whole share. BioRestorative Therapies operates in the biotechnology industry, developing regenerative medicine products using cell and tissue protocols.

BioRestorative Therapies, Inc. dismissed CBIZ CPAs P.C. as its independent auditor effective August 28, 2026, and engaged Bush & Associates CPA for the fiscal year ending December 31, 2026. The previous auditor's report on the 2025 financial statements included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern. Katharyn Field resigned as Interim CEO, CFO, Treasurer, Secretary, and Board member effective August 26-31, 2026, entering into a consulting agreement for $10,000 monthly. The Board appointed Mika Grasso as Interim CEO and Anna Skowron as fractional CFO, both on consulting agreements with monthly fees of $10,000 and $12,000 respectively. Steven Brown was named Audit Committee Chair and Chairman of the Board. BioRestorative Therapies operates in the biotechnology industry, focusing on developing cell-based therapies.

BioRestorative Therapies, Inc. received a delinquency notification from Nasdaq on August 21, 2026, for failing to timely file its Form 10-Q for the quarter ended June 30, 2026, violating Listing Rule 5250(c)(1). The company has until October 20, 2026, to submit a compliance plan and may receive an extension until February 16, 2027. Failure to regain compliance could result in delisting from the Nasdaq Capital Market under symbol BRTX. BioRestorative Therapies, Inc. operates in the biotechnology industry, developing cell-based therapies for regenerative medicine.

On August 7, 2026, BioRestorative Therapies, Inc. suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines pending a business review and regulatory assessment. The company has not decided to discontinue these products but is reviewing documentation, sourcing, and regulatory status. This operational halt introduces uncertainty regarding near-term revenue from these lines and potential associated costs. BioRestorative Therapies, Inc. operates in the biotechnology sector, developing regenerative medicine therapies and biocosmeceutical skincare products.